Clarity Pharmaceuticals Ltd (ASX: CU6) shares are catching the eye on Monday.
In morning trade, the ASX 300 stock is up a sizeable 18% to $3.38.
Image source: Getty Images
Why is this ASX 300 stock jumping?
Investors have been buying this clinical-stage radiopharmaceutical company's shares after it released key findings from its Co-PSMA Phase II Investigator-Initiated Trial, which compared 64Cu-SAR-bisPSMA against 68Ga-PSMA-11 in 50 prostate cancer patients experiencing biochemical recurrence following surgery.
According to the release, the ASX 300 stock reported that 64Cu-SAR-bisPSMA more than doubled the number of prostate cancer lesions detected per patient compared to the standard-of-care scan. On average, patients had 1.26 lesions detected using Clarity's product versus 0.48 using 68Ga-PSMA-11. The difference was statistically significant (p <0.0001).
In total, the standard scan detected 24 lesions across all patients. Clarity's next-day imaging detected 63 lesions.
Even more notably, at a per-patient level, only 36% of patients had a positive scan using 68Ga-PSMA-11. By comparison, 78% of patients were identified as having prostate cancer recurrence using 64Cu-SAR-bisPSMA.
That means around four out of five patients had disease detected using Clarity's product, versus just over one in three with the current standard scan.
Why is this important?
Prostate cancer patients with rising PSA levels after surgery often face uncertainty if imaging fails to detect the site of recurrence. More sensitive imaging can directly influence treatment decisions.
According to the announcement, planned patient management changed in 44% of trial participants after assessment with 64Cu-SAR-bisPSMA. That is a significant clinical impact.
The abstract outlining these findings has been accepted for oral presentation at the 2026 European Association of Urology Congress, one of the largest urology conferences globally.
'Exceptional'
Commenting on the news, the ASX 300 stock's executive chair, Dr Alan Taylor, said:
The data from the Co-PSMA trial are nothing short of exceptional. We already knew of the significant benefits of the optimised bisPSMA molecule from the early days around 7 years ago, when it was purposely developed to overcome the many shortfalls of the current single-targeting SOC PSMA imaging agents.
This innovative benchtop research of the dual-targeting bisPSMA agent quickly progressed to multiple clinical trials, including COBRA6, PROPELLER7 and SECuRE8, which enabled us to secure three Fast Track Designations from the United States (US) Food and Drug Administration (FDA) and advance to two registrational trials, AMPLIFY9 and CLARIFY10, both of which are nearing completion of recruitment.
